Table 1. ASS1 expression in normal and malignant lymphoid tissues.
| Lymphoma subtypes | % ASS1-negative cases (n) | % ASS1 promoter methylationa (n) |
|---|---|---|
| Normal tissue (spleen, reactive lymph node and tonsil) | 85 (11/13) | 0 (0/10) |
| Follicular lymphoma | 100 (38/38) | 80 (8/10) |
| Diffuse large B-cell lymphoma | 100 (66/66) | 70 (7/10) |
| Marginal zone lymphoma | 96 (26/27) | 70 (7/10) |
| Burkitt's lymphoma | 100 (8/8) | 50 (3/6) |
| Cutaneous T-cell lymphoma | 64 (18/28) | 50 (5/10) |
| Mantle cell lymphomab | 98 (90/91; 31/32)c | 70 (7/10) |
| Hodgkin's lymphomab | 97 (173/179; 50/50)d | 70 (5/7) |
Abbreviation: ASS1, argininosuccinate synthetase
a
Based on MS-PCR analysis of 6–10 samples
b
ASS1 expression in serial biopsies (baseline; relapse)
c
Single patient with ASS1-positive biopsy at baseline and relapse
d
No relapse biopsies available for baseline ASS1 expressors